Icecure Medical (Icecure Medical) Cash, Cash Equivalents, Marketable Securities : $11.06 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Icecure Medical Cash, Cash Equivalents, Marketable Securities?

Icecure Medical's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($3.03 Mil) to Sep. 2023 ($3.83 Mil) and increased from Sep. 2023 ($3.83 Mil) to Dec. 2023 ($11.06 Mil).

Icecure Medical's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($25.62 Mil) to Dec. 2022 ($23.66 Mil) and declined from Dec. 2022 ($23.66 Mil) to Dec. 2023 ($11.06 Mil).

Icecure Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Icecure Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icecure Medical Cash, Cash Equivalents, Marketable Securities Chart

Icecure Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

5.78

3.50

25.62

23.66

11.06

Icecure Medical Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															23.66	5.59	3.03	3.83	11.06

Icecure Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Icecure Medical (NAS:ICCM) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Icecure Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Icecure Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Icecure Medical (Icecure Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Icecure Medical Ltd (NAS:ICCM) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Haeshel Street, Southern Industrial Park, PO Box 3163, Caesarea, ISR, 3079504

Website

https://www.icecure-medical.com

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.